Eva Dahlen

Senior Director, Search & Evaluation at Novo Nordisk

Speaker

Dr. Eva Dahlén holds a position as Director, Cardiometabolic Evaluation, in Search & Evaluation at Novo Nordisk. In this capacity, she takes a leading role in overseeing and managing partnering activities in diabetes. She also has several years of experience in S&E across a range of technology areas, including RNA & gene therapy, oral and alternative delivery of biologics, and AI/ML-enabled target and drug discovery. Eva has led numerous due diligences, including those leading to partnerships with Ascendis pharma and Valo Health. Prior to Novo Nordisk, Eva held various positions in business development and R&D at the immuno-oncology company, Alligator Bioscience. She has a scientific background in immunology and oncology and holds a Ph.D. in immunology.